Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
More than 90% of oncology new molecular entities (NMEs) that demonstrate efficacy in animal studies fail in clinical trials. Preclinical pharmacology model selection is where the solution begins.
Why Traditional Preclinical Oncology Models Fall Short
Xenograft models and genetically engineered mouse models have served as the workhorses of preclinical oncology pharmacology for decades.
They cannot adequately replicate human tumour heterogeneity, immune-tumour microenvironment interactions, or the complex adaptive responses that determine whether an NME will achieve clinical benefit in humans.
The consequence is systematic translational failure.
When a compound clears preclinical hurdles that don't reflect human tumour biology, it enters Phase I or Phase II clinical trials carrying safety and efficacy assumptions that the biology won't support. The result is attrition at the most expensive stage of development.
The FDA's 2025 oncology drug development landscape reflected a more selective regulatory stance, with approvals favouring well-validated mechanisms supported by rigorous translational data.
Approximately 16 new oncology therapies (15 of which are NMEs) and more than 30 supplemental indications were approved during the year, but the pattern suggests the bar for preclinical justification is rising.
The Shift to High-Fidelity Translational Models
Three model categories are reshaping the preclinical pharmacology toolkit for oncology NMEs:
Patient-derived xenografts (PDX) transplant human tumour tissue directly into immunocompromised mice, preserving the genetic and histological characteristics of the original tumour.
This fidelity makes PDX models substantially more predictive of clinical response than cell-line xenografts, particularly for NMEs targeting driver mutations where molecular stratification is essential.
Organoids are three-dimensional tumour models grown from patient-derived cells that reproduce the architecture and functional characteristics of the parent tumour.
They can be rapidly scaled for drug screening, co-clinical trial designs where organoids from enrolled patients are tested alongside the clinical protocol, and biomarker discovery.
Regulatory agencies, including the European Medicines Agency, are formalising qualification pathways for organoid-based evidence.
Humanised immune models are essential for oncology NMEs where the mechanism of action involves immune engagement, such as with checkpoint inhibitors, cell and gene therapy (CGT) products, and bispecific antibodies.
Without modelling the human immune-tumour interface, preclinical efficacy data for these modalities carries very limited translational value.
Biomarker Strategy as a Preclinical Priority
The most consequential decisions in oncology drug development happen before Phase I clinical trials begin.
Predictive biomarker identification and validation at the preclinical stage determines which patient populations the NME can rationally target, informs inclusion and exclusion criteria, and provides the mechanistic evidence regulators expect to see in an Investigational New Drug application.
Molecular stratification across tumour biology is now a core regulatory expectation.
The 2025 oncology regulatory landscape saw continued refinement of patient selection strategies across KRAS subtypes, HER2-low, and EGFR Exon20ins — all enabled by robust preclinical biomarker programmes.
Asciminib, an allosteric small-molecule tyrosine kinase inhibitor, provides a useful case study. Preclinical pharmacology data showed asciminib was approximately 4 to 13 times more potent against wild-type BCR-ABL1 tumours than tumours harbouring the T315I mutation.
That finding directly informed the decision to run separate Phase I dose escalations for wild-type and T315I-mutant patient cohorts, representing a mechanistically justified and regulatorily sound translational strategy.
New Approach Methodologies and Pharma Regulatory Reform
The U.S. FDA Modernization Act 2.0 formally opened the door to non-animal testing methods for drug development submissions.
New Approach Methodologies (NAMs) — including patient-derived organoids, organ-on-chip platforms, and AI-driven computational models — are now accepted as evidence in Investigational New Drug applications for oncology NMEs.
Physiologically based pharmacokinetic (PBPK) modelling and quantitative systems pharmacology (QSP) are demonstrating particular value in improving translational accuracy, reducing animal study requirements, and providing mechanistic clarity on drug-target interactions that conventional animal models can't.
Antibody-drug conjugates (ADCs) delivered the strongest momentum across FDA approvals in 2025.
ADC preclinical programmes require especially sophisticated translational strategies: Payload toxicity profiling, linker stability, bystander effect characterisation, and tumour antigen heterogeneity must all be addressed in preclinical pharmacology before a dose range for Phase I can be justified.
NAM Strategic Recommendations for Oncology R&D Leaders
Three priorities should anchor preclinical pharmacology strategy for oncology NMEs in 2026:
- Model selection is a strategic decision, not a default: The choice between xenografts, PDX, organoids, and humanised models should be driven by the NME's mechanism of action, target population, and the specific translational question being answered. Default to the highest-fidelity model your budget supports.
- Biomarker programmes should start at target identification: Predictive biomarker hypotheses that are generated early and tested systematically in preclinical models produce Investigational New Drug applications with stronger mechanistic narratives — and lower Phase II failure risk.
- Engage regulatory science early: Pre-Investigational New Drug meetings with the FDA's INTERACT programme allow sponsors to discuss NAM strategies and translational evidence packages before committing to a full preclinical programme. This early alignment reduces the risk of generating data that regulators will not accept.
Building More Predictive Oncology Development Programmes
As oncology drug development becomes increasingly targeted and biologically complex, the quality of preclinical evidence is becoming a decisive factor in clinical and commercial success.
Traditional animal models remain valuable in specific contexts, but they are no longer sufficient on their own to support the next generation of oncology new molecular entities (NMEs).
Higher-fidelity translational models, predictive biomarker strategies, and New Approach Methodologies (NAMs) are enabling sponsors to generate more clinically relevant evidence, improve regulatory confidence, and reduce costly late-stage attrition.
For R&D leaders, preclinical pharmacology is a strategic opportunity to strengthen development programmes from the outset.
Organisations that invest early in robust translational science, fit-for-purpose model selection, and regulator-ready evidence packages will be better positioned to accelerate development, improve clinical success rates, and bring innovative oncology therapies to patients more efficiently.
Pharmatica monitors the evolving preclinical pharmacology landscape across oncology modalities, giving R&D executives the analytical clarity to make high-stakes model selection decisions with confidence.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What are preclinical pharmacology models in oncology?
Preclinical pharmacology models in oncology are laboratory systems used to test the safety and efficacy of new molecular entities before human trials. They include cell-line xenografts, patient-derived xenografts (PDX), organoids, and humanised immune models. Each has different levels of translational fidelity to human tumour biology.
Why do most oncology drugs fail despite positive preclinical results?
Over 90% of oncology new molecular entities that succeed in animal studies fail in clinical trials. Traditional models cannot adequately replicate human tumour heterogeneity, immune-tumour microenvironment interactions, or patient-specific molecular responses — meaning preclinical signals often don't predict clinical outcomes.
What are patient-derived xenografts and why do they matter?
Patient-derived xenografts (PDX) transplant human tumour tissue into immunocompromised mice, preserving the original tumour's genetic and histological characteristics. This makes them more predictive of clinical response than conventional cell-line models, especially for NMEs targeting specific driver mutations.
What is the FDA Modernization Act 2.0 and how does it affect preclinical testing?
The FDA Modernization Act 2.0 allows New Approach Methodologies — including organoids, organ-on-chip platforms, and AI-driven computational models — to be submitted as evidence in Investigational New Drug applications. This reduces mandatory animal testing and opens regulatory pathways for higher-fidelity human-relevant preclinical data.
How does biomarker strategy improve oncology NME development?
Predictive biomarker identification at the preclinical stage allows teams to define the patient population most likely to respond, inform clinical protocol inclusion criteria, and provide mechanistic evidence for regulatory submissions. Early biomarker validation directly reduces Phase II failure risk by ensuring clinical trials are run in the right patient cohort.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)